Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 12/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 3/20 | 0.38 |
| ▸ | BCR | P11274 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.37 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.37 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29390006 | 1.00 | PDE7A (0.42) | PDE7AGRIN2BABL1BCREPHX2 | |
| SCHEMBL29388250 | 0.85 | PDE7A (0.44) | PDE7AEPHX2NPC1RAB9A | |
| SCHEMBL21146531 | 0.85 | PDE7A (0.44) | PDE7AEPHX2NPC1RAB9A | |
| SCHEMBL29391244 | 0.83 | RAF1 (0.44) | PDE7AKCNJ6KCNJ5KCNJ3BACE1 | |
| SCHEMBL21062742 | 0.83 | RAF1 (0.44) | PDE7AKCNJ6KCNJ5KCNJ3BACE1 | |
| SCHEMBL29390725 | 0.82 | HTR2B (0.42) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL21145868 | 0.82 | HTR2B (0.42) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL21146085 | 0.81 | RAF1 (0.48) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL21146099 | 0.81 | PTPN11 (0.42) | BACE1BACE2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL21145814 | 0.79 | ACKR3 (0.40) | PDE7AGRIN2BKCNJ6KCNJ5KCNJ3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11247965-B2 | Hepatitis B capsid assembly modulators | VenatoRx Pharmaceuticals, Inc. (US) | 2022-02-15 | — | — | US | disclosed |
| US-11247965-B2 | Hepatitis B capsid assembly modulators | VenatoRx Pharmaceuticals, Inc. (US) | 2022-02-15 | — | — | US | disclosed |
| US-20210171439-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | VenatoRx Pharmaceuticals, Inc. (US) | 2021-06-10 | — | — | US | disclosed |
| US-20210171439-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | VenatoRx Pharmaceuticals, Inc. (US) | 2021-06-10 | — | — | US | disclosed |
| WO-2019118358-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | VenatoRx Pharmaceuticals, Inc. (US) | 2019-06-20 | — | — | WO | disclosed |
| WO-2019118358-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | VenatoRx Pharmaceuticals, Inc. (US) | 2019-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171439-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | HAVCR2, COPB1, HDLBP | PDE7A 2706/4885GRIN2B 1492/4885ABL1 3486/4885 |
| US-11247965-B2 | Hepatitis B capsid assembly modulators | HAVCR2, COPB1, HDLBP | PDE7A 2706/4885GRIN2B 1492/4885ABL1 3486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.